GT Biopharma (GTBP) Proxy Filing summary

Executive summary

• Annual meeting scheduled for July 24, 2025, with voting available online or in person.

• Shareholders are asked to vote on director elections, auditor ratification, executive compensation, share issuance, and incentive plan amendment.

Voting matters and shareholder proposals

• Election of four directors for a one-year term: Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin.

• Ratification of Weinberg & Company, P.A. as independent public accountants for 2025.

• Advisory vote on executive compensation as disclosed in the proxy statement.

• Approval of issuance of 19.99% or more of outstanding shares in connection with securities purchase agreements.

• Amendment to the 2022 Omnibus Incentive Plan to increase shares available for awards by 583,334 shares.

Board of directors and corporate governance

• Four nominees are presented for election to the board for a one-year term.